University of Queensland scientists have successfully protected mice from the Covid-19 virus by administering a US-developed vaccine candidate with a ‘patch’, rather than a needle.
The University of Texas Hexapro vaccine candidate, delivered via the UQ-developed and Vaxxas-commercialised high-density microarray patch (HD-MAP), provided protection against Covid-19 disease with a single, pain-free ‘click’ from a pocket-sized applicator.“When the Hexapro vaccine is delivered via HD-MAP applicator – rather than a needle – it produces better and faster immune responses,” Dr Muller said. It also neutralises multiple variants, including the UK and South Africa variants. And it’s much more user-friendly than a needle – you simply ‘click’ an applicator on the skin, and 5000 microscopic projections almost-imperceptibly deliver vaccine into the skin. The UQ team, together with Vaxxas, hope to take the technology to the world and are looking for funding opportunities to accelerate to clinical trials as soon as possible.”
Dr Muller said that Hexapro, delivered by the high-density microarray patch, could dramatically assist global vaccine rollout effort, particularly for billions of vulnerable people in low- and middle-income countries.
Muller continued: “We’ve shown this vaccine, when dry-coated on a patch, is stable for at least 30 days at 25 degrees Celsius and one week at 40 degrees, so it doesn’t have the cold chain requirements of some of the current options.”
President and CEO of Vaxxas, David L. Hoey, said: “These results are extremely clear – vaccination by HD-MAP produces much stronger and more protective immune responses against Covid-19 in model systems than via needle or syringe. […] The prospect of having a single-dose vaccine, that could be easily distributed and self-administered, would greatly improve global pandemic vaccination capabilities.”
This study was funded through an Advance Queensland Industry Fellowship in partnership with Vaxxas and Technovalia, with vital contributions from Professor Nigel McMillan and Griffith University’s Menzies Health Institute.
Image credit: Vaxxas